ENTITY

Sinopep-Allsino Bio Pharmaceutical (688076 CH)

13
Analysis
Health CareChina
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. researches, develops, manufactures, and sells peptide drugs and small molecule drugs. The Company produces liraglutide, somalutide, alogliptin benzoate, bivalirudin, eptifibatide, and more. Sinopep-Allsino Bio Pharmaceutical applies its products in treatment of diabetes, cardiovascular diseases, tumors, and other fields.
more
15 Oct 2024 15:42

Quiddity Leaderboard CSI Medical Service Dec 24: US$271mn One-Way; 1x-4x ADV to Trade for Most Names

We estimate the CSI Medical December 2024 index rebalance to trigger flows of US$271mn one-way. Most of the expected ADDs/DELs have 1x-4x ADV to...

Share
23 Sep 2024 05:08

Quiddity Leaderboard CSI Medical Dec 24: 5 Changes Possible; Exp ADDs yet to Outperform Exp DELs

We expect US$187mn one-way flows. Most of the expected ADDs/DELs have 1x-4x ADV to trade. The expected ADDs have failed to outperform the the...

Share
19 Dec 2024 18:27

Quiddity Leaderboard STAR 50/100 Mar25: Multiple Changes, Large Flows; High-Impact Trade Idea

We believe the STAR 50 expected ADDs could continue to outperform the STAR 50 expected DELs over the next few weeks. All of these names have 3.5x...

Share
bullishSansure Biotech
01 Dec 2024 12:00

Quiddity CSI Medical Dec 24 Results: 3 Changes; All Expected; US$362mn One-Way

We estimate one-way flow to be US$362mn. The Inclusion/Exclusion events will take place at the close of trading on 13th December 2024.

Share
30 Nov 2024 13:38

STAR50/STAR100 Index Rebalance: No Changes for STAR50; 4 Changes for STAR100

As forecast, there are no changes for STAR50 and 4 for STAR100. Big selling in SMIC due to capping. Hainan Jinpan's inclusion could surprise the...

Logo
463 Views
Share
x